9/9/2023 0 Comments 4d molecular therapeutics logo![]() ![]() 4D-710 for Cystic Fibrosis Lung Disease:.Initial interim 4D-150 for DME Phase 2 data expected in H1 2024. ![]() Enrollment of the Phase 2 SPECTRA clinical trial for DME expected to begin in Q3 2023.Initial interim 4D-150 for wet AMD Phase 2 data expected in H1 2024.Enrollment of the Phase 2 randomized Dose Expansion stage of the PRISM clinical trial expected to complete in Q3 2023.and announced sCFH as payload for 4D-175 product candidate for GA Acquired the rights and know-how for sCFH from Aevitas Therapeutics, Inc.Enrollment in Phase 2 Dose Expansion (n=50) stage of the PRISM is more than 50% completed.In the 3E10 vg/eye cohort, 4 of 4 (100%) of Phase 2 BCVA-eligible patients remained injection-free at 36 weeks with a mean reduction in central subfield thickness (CST) of 72µm.Dose response observed in favor of 3E10 vg/eye vs lower doses of 1E10 and 6E9 vg/eye.All three doses were well-tolerated and demonstrated clinical activity.Presented positive interim data from the three dose cohorts studied (3E10, 1E10, and 6E9 vg/eye n=5 each) in the Dose Exploration stage of the Phase 1/2 PRISM clinical trial for wet AMD in April at the ARVO 2023 Conference.Significant progress advancing the 4D-150 program for the intravitreal treatment of patients with wet AMD and with DME.Recent Highlights in Large Market Ophthalmology Portfolio Our capital-efficient operations and strong cash position are expected to support operations into the first half of 2026.” “We believe we have the opportunity to build a franchise in large market ophthalmology with 4D-150 for the treatment of wet AMD and diabetic macular edema (DME) and 4D-175 in for GA, each using our retinotropic vector R100. We also announced the acquisition of the rights and know-how for sCFH from Aevitas for use in our preclinical product candidate 4D-175 for treatment of GA,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. We are excited to see faster than expected enrollment of the Phase 2 Dose Expansion stage of the PRISM trial and believe this highlights the belief by investigators that 4D-150 has potential to be a transformative treatment for patients with wet AMD. We observed excellent tolerability and clinical activity in these high anti-VEGF need patients that we believe support a differentiated profile. In April at ARVO, we released positive interim clinical data on all three dose cohorts in the Dose Exploration stage of our Phase 1/2 PRISM clinical trial of 4D-150 for the treatment of wet AMD. “We are pleased with the progress of our large market ophthalmology portfolio this year. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |